Emergent Biosolutions (NYSE:EBS) Rating Increased to Hold at Zacks Research

Key Points

• Zacks Research upgraded Emergent BioSolutions to a “Hold” rating. Analyst opinions remain mixed, with three Buy ratings, one Hold and one Sell; the consensus price target is $10.
• Shares opened at $4.55, near the company’s 12-month low of $4.36 and well below its 50-day and 200-day moving averages. The stock has a market capitalization of about $233 million.
• Emergent reported quarterly EPS of $0.60, beating the estimate of a $0.08 loss, while revenue of $234.3 million exceeded expectations. However, analysts forecast a full-year loss of $4.63 per share, and increased competition and pricing pressure have led to a $191.3 million non-cash impairment charge against its NARCAN franchise.

Emergent Biosolutions (NYSE:EBS - Get Free Report) was upgraded by equities research analysts at Zacks Research to a "hold" rating in a note issued to investors on Tuesday,Zacks.com reports.

A number of other research analysts have also issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Emergent Biosolutions in a research note on Friday, August 7th. Benchmark reissued a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. HC Wainwright decreased their price target on shares of Emergent Biosolutions from $12.00 to $10.00 and set a "buy" rating for the company in a report on Monday. Finally, UBS Group reaffirmed a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $10.00.

Emergent Biosolutions Stock Up 2.2%

EBS opened at $4.55 on Tuesday. The firm has a market cap of $233.29 million, a P/E ratio of -1.28 and a beta of 2.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. The business has a 50 day moving average price of $7.59 and a 200 day moving average price of $8.60. Emergent Biosolutions has a twelve month low of $4.36 and a twelve month high of $14.06.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%.The company had revenue of $234.30 million for the quarter, compared to the consensus estimate of $177.50 million. Research analysts forecast that Emergent Biosolutions will post -4.63 EPS for the current year.

Insider Buying and Selling at Emergent Biosolutions

In other news, SVP Paul Anthony Williams sold 3,000 shares of the firm's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the sale, the senior vice president owned 159,098 shares in the company, valued at approximately $1,336,423.20. This trade represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.00% of the company's stock.

Institutional Trading of Emergent Biosolutions

Hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new stake in Emergent Biosolutions in the 2nd quarter worth $31,000. Torren Management LLC acquired a new position in shares of Emergent Biosolutions during the fourth quarter valued at about $37,000. CANADA LIFE ASSURANCE Co bought a new stake in shares of Emergent Biosolutions in the fourth quarter valued at about $45,000. Raymond James Financial Inc. bought a new stake in shares of Emergent Biosolutions in the second quarter valued at about $53,000. Finally, Farther Finance Advisors LLC grew its position in Emergent Biosolutions by 361.3% during the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company's stock worth $76,000 after buying an additional 4,827 shares in the last quarter. 78.40% of the stock is owned by institutional investors.

More Emergent Biosolutions News

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $10 price target. The firm projects Emergent will return to profitability in 2027, forecasting fiscal 2027 EPS of $0.28 after an estimated fiscal 2026 loss of $4.63 per share. Longer-term earnings expectations provide a potential recovery catalyst if the company stabilizes operations. HC Wainwright forecast article
• Neutral Sentiment: Management’s Q2 2026 earnings call transcript is now available. Investors are likely examining the call for additional detail on the NARCAN franchise, competitive conditions, pricing, cost controls and the path toward the projected 2027 profitability. Emergent BioSolutions Q2 2026 earnings call transcript
• Negative Sentiment: Emergent disclosed a $191.3 million non-cash impairment charge against its NARCAN franchise. The write-down was attributed to increased competition and pricing pressure in the naloxone market, raising concerns about the franchise’s future revenue and profitability. Levi and Korsinsky investor investigation notice
• Negative Sentiment: A law firm announced an investor investigation following shareholder losses. Although the announcement does not establish wrongdoing, the investigation adds legal and reputational risk and may increase volatility.
• Negative Sentiment: Near-term earnings forecasts remain weak. HC Wainwright expects losses of $0.75 per share in Q3 2026 and $0.64 in Q4 2026, reinforcing concerns that the impairment and NARCAN market pressures will continue affecting results.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source